prof.dr. (Carin) CA Uyl - de Groot | Erasmus University Rotterdam

Full professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Burg. Oudlaan 50, Rotterdam
Room: J8-35
Email: uyl@eshpm.eur.nl

More information

Profile

Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.

MG (Margreet) Franken, B (Brenda) Leeneman, Maureen J.B. Aarts, ACJ van Akkooi, F. W.P.J. van den Berkmortel, M. J. Boers-Sonderen, Alphonsus J.M. Van Den Eertwegh, Jan-Willem B de Groot, Geke A.P. Hospers, Ellen W. Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, A.A.M. (Astrid) van der Veldt, HM Westgeest, Michel W.J.M. Wouters, J. B.A.G. Haanen & CA (Carin) Uyl - de Groot (2021) - Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs - ESMO Open, 6 (6) - doi: 10.1016/j.esmoop.2021.100320
Laurenske A. Visser, Marc Folcher, Claudia Delgado Simao, Biotza Gutierrez Arechederra, Encarna Escudero, Carin A. Uyl-de Groot & William Ken Redekop (2021) - The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis - PharmacoEconomics - doi: 10.1007/s40273-021-01081-y
Sven Van Egmond, Loes M. Hollestein, Carin A. Uyl-De Groot, Judith A. Van Erkelens, Marlies Wakkee & Tamar E.C. Nijsten (2021) - Practice Variation in Skin Cancer Treatment and Follow-Up Care - Dermatology, 237 (6), 1000-1006 - doi: 10.1159/000513523
Frederick W. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F.M. Posthuma, Wendy B.C. Stevens, Carin A Uyl-de Groot & Hedwig M. Blommestein (2021) - Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma - Expert Review of Anticancer Therapy, 21 (12), 1411-1422 - doi: 10.1080/14737140.2021.1971520
Brenda Leeneman, Kay Schreuder, Carin A. Uyl - de Groot, Alexander C.J. van Akkooi, John B.A.G. Haanen, Marlies Wakkee, Margreet G. Franken & Marieke W.J. Louwman (2021) - Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018) - European Journal of Cancer, 154, 111-119 - doi: 10.1016/j.ejca.2021.06.007
B (Brenda) Leeneman, K Schreuder, CA (Carin) Uyl - de Groot, ACJ (Alexander) van Akkooi, JBAG Haanen, M. (Marlies) Wakkee, MG (Margreet) Franken & MWJ Louwman (2021) - Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study - European Journal of Cancer, 2021 (154), 111-119 - doi: 10.1016/j.ejca.2021.06.007
Martijn J.H.G. Simons, Valesca P. Retèl, Bram L.T. Ramaekers, Rogier Butter, Joanne M. Mankor, Marthe S. Paats, Joachim G.J.V. Aerts, Zakile A. Mfumbilwa, Paul Roepman, Veerle M.H. Coupé, Carin A. Uyl-de Groot, Wim H. van Harten & Manuela A. Joore (2021) - Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer - PharmacoEconomics, 39 (12), 1429-1442 - doi: 10.1007/s40273-021-01073-y
Laurenske A. Visser, Celine Louapre, Carin A. Uyl-de Groot & WK (Ken) Redekop (2021) - Health-related quality of life of multiple sclerosis patients - Archives of Public Health, 79 (1) - doi: 10.1186/s13690-021-00561-z
Lytske J. Bakker, Lucas M.A. Goossens, Maurice J. O'Kane, Carin A. Uyl-de Groot & William K. Redekop (2021) - Analysing electronic health records - Health Policy and Technology, 10 (3) - doi: 10.1016/j.hlpt.2021.100545
Milanne M.J. Galekop, Carin A. Uyl-de Groot & W. Ken Redekop (2021) - A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults - Value in Health, 24 (3), 325-335 - doi: 10.1016/j.jval.2020.12.006
Hedwig Blommestein, Margreet Franken, CHY van Beurden-Tan, NMA Blijlevens, PC Huijgens, Pieter Sonneveld, Carin Groot & S Zweegman (2021) - Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma - JAMA network open, 4 (3) - doi: 10.1001/jamanetworkopen.2021.3497
Renaud Heine, Frederick W. Thielen, Marc Koopmanschap, Marie José Kersten, Hermann Einsele, Ulrich Jaeger, Pieter Sonneveld, Jorge Sierra, Carin Smand & Carin A. Uyl-De Groot (2021) - Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers - HemaSphere, 5 (2) - doi: 10.1097/HS9.0000000000000524
Jelle Walraven, Maartje S. Jacobs & Carin A. Uyl-de Groot (2021) - Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare - Value in Health, 24 (7), 1038-1044 - doi: 10.1016/j.jval.2021.01.010
Lytske Bakker, Jos Aarts, Carin Groot & Ken Redekop (2020) - Economic evaluations of big data analytics for clinical decision-making: a scoping review - Journal of the American Medical Informatics Association - doi: 10.1093/jamia/ocaa102
Marianne Luyendijk, RWM Vernooij, Hedwig Blommestein, S Siesling & Carin Groot (2020) - Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review - Value in Health, 23 (11), 1497-1508 - doi: 10.1016/j.jval.2020.05.008 - [link]
Eline Noels, Loes Hollestein, K Luijkx, M Louwman, Carin Groot, Renate Bos, Astrid Veldt, Dirk Grünhagen & Marlies Wakkee (2020) - Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007-2017 - Acta Dermato-Venereologica, 100 - doi: 10.2340/00015555-3463
Tobias Polak, Joost Rosmalen & Carin Groot (2020) - Response to Open Peer Commentary "Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs" - American Journal of Bioethics, 20 (11), W4-W5 - doi: 10.1080/15265161.2020.1820113
Tobias Polak, Joost Rosmalen & Carin Groot (2020) - Expanded Access as a source of real-world data: An overview of FDA and EMA approvals - British Journal of Clinical Pharmacology, 86 (9), 1819-1826 - doi: 10.1111/bcp.14284
Frederick Thielen, Maite Houwing, Marjon Cnossen, IA Hadithy-Irgiztseva, Jan Hazelzet, Carin Groot, Anne Pagter & Hedwig Blommestein (2020) - Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country - Pediatric Blood & Cancer, 67 (9) - doi: 10.1002/pbc.28588
Margreet Franken, Tim Kanters, JL Coenen, P De Jong, Agnes Jager & Carin Groot (2020) - Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab - Breast, 52, 71-77 - doi: 10.1016/j.breast.2020.05.001
Carin Groot, RJ Heine, HM Krol & Jaap Verweij (2020) - Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe - Cancers, 12 (8), 1-17 - doi: 10.3390/cancers12082313 - [link]
Brenda Leeneman, Carin Groot, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JW de Groot, KH Herbschleb, JJ van der Hoeven, GA Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, Astrid Veldt, G Vreugdenhil, M Wouters, J Haanen & Margreet Franken (2020) - Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs - Cancers, 12 (4) - doi: 10.3390/cancers12041003
Malou Kuppen, HM Westgeest, AJM Van den Eertwegh, J Coenen, RJA van Moorselaar, P Berg, MM Geenen, N Mehra, MP Hendriks, MI Lampe, ACM van de Luijtgaarden, FPJ Peters, TA Roeleveld, TJ Smilde, Ronald Wit, IM van Oort, WR Gerritsen & Carin Groot (2020) - Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands - Clinical Genitourinary Cancer, 18 (3), E233-E253 - doi: 10.1016/j.clgc.2019.11.015
Laurenske Visser, C Louapre, Carin Groot & Ken Redekop (2020) - Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review - Multiple Sclerosis and Related Disorders, 39, 101929 - doi: 10.1016/j.msard.2020.101929
Carin Groot, MS Schuurman, PC Huijgens & J Praagman (2020) - Fewer cancer diagnoses during the COVID-19 epidemic according to diagnosis, age and region - Tijdschrift voor Gezondheidswetenschappen, 1-8 - doi: 10.1007/s12508-020-00289-1
PHJ Slootbeek, ML Duizer, MJ Doelen, ISH Kloots, Malou Kuppen, HM Westgeest, Carin Groot, S Pamidimarri Naga, MJL Ligtenberg & IM van Oort (2020) - Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer - International Journal of Cancer, 148 (2), 385-395 - doi: 10.1002/ijc.33306
Kevin Veen, IB de Angst, Mostafa Mokhles, HM Westgeest, Malou Kuppen, Carin Groot, WR Gerritsen, PJM Kil & Hanneke Takkenberg (2020) - A clinician’s guide for developing a prediction model: a case study using real?world data of patients with castration?resistant prostate cancer - Journal of Cancer Research and Clinical Oncology, 146, 2067-2075 - doi: 10.1007/s00432-020-03286-8
Neil E. Rens, Carin A. Uyl-De Groot, Jeremy D. Goldhaber-Fiebert, Julio Croda & Jason R. Andrews (2020) - Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis - Clinical Infectious Diseases, 71 (12), 3136-3143 - doi: 10.1093/cid/ciz1212
Carin A. Uyl-de Groot, Rachel Ramsden, Dawn Lee, Janneke Boersma, Sonja Zweegman & Sujith Dhanasiri (2020) - Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation - European Journal of Haematology, 105 (5), 635-645 - doi: 10.1111/ejh.13497
Mira D. Franken, Anne De Hond, Koen Degeling, Cornelis J.A. Punt, Miriam Koopman, Carin A. Uyl-De Groot, Matthijs M. Versteegh & Martijn G.H. Van Oijen (2020) - Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01481-2
Malou C.P. Kuppen, H.M. (Hans) Westgeest, Maarten J. Van Der Doelen, Alphonsus J.M. Van Den Eertwegh, Jules L.L.M. Coenen, Katja K.H. Aben, Alphons C.M. Van Den Bergh, Andries M. Bergman, Joan Van Den Bosch, Filiz Celik, Mathijs P. Hendriks, Jules Lavalaye, Saskia Van Der Meer, Marco B. Polee, Diederik M. Somford, Inge M. Van Oort, Carin A. Uyl-De Groot & Winald R. Gerritsen (2020) - Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer - Future Oncology, 16 (19), 1371-1384 - doi: 10.2217/fon-2020-0039
Jessica C.L. Notohardjo, Malou C.P. Kuppen, Hans M. Westgeest, Reindert J.A. van Moorselaar, Niven Mehra, Jules L.L.M. Coenen, Inge M. van Oort, Aad I. de Vos, Walter L. Vervenne, Alphons C.M. van den Bergh, Katja K.H. Aben, Diederik M. Somford, Andries M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen & Alfons J.M. van den Eertwegh (2020) - Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population - European Urology Focus - doi: 10.1016/j.euf.2020.03.009
Ria de Kleijn, Carin Uyl-de Groot, Chris Hagen, Casper Franssen, Jeanette Schraa, Pieternel Pasker-de Jong & Piet ter Wee (2020) - CHANGING NURSING CARE TIME AS AN EFFECT OF CHANGED CHARACTERISTICS OF THE DIALYSIS POPULATION - Journal of Renal Care, 46 (3), 161-168 - doi: 10.1111/jorc.12326
Henri B. Wolff, Leonie Alberts, Naomi van der Linden, Mathilda L. Bongers, Naomi E. Verstegen, Frank J. Lagerwaard, Frederik N. Hofman, Carin A. Uyl-de Groot, Suresh Senan, Sherif Y. El Sharouni, Elisabeth A. Kastelijn, Franz M.N.H. Schramel & Veerle M.H. Coupé (2020) - Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer - Lung Cancer, 141, 89-96 - doi: 10.1016/j.lungcan.2020.01.011
Anton Hagenbeek, John Gribben, Ulrich Jäger, Peter Kapitein, Giampaolo Merlini, Maria Piggin, Carin A. Uyl-De Groot & Robin Doeswijk (2020) - Fair pricing of innovative medicines - HemaSphere, 4 (5) - doi: 10.1097/HS9.0000000000000488
Margreet Franken, Brenda Leeneman, Maria Gheorghe, Carin Groot, JBAG Haanen & Pieter Baal (2019) - A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma - European Journal of Cancer, 123, 58-71 - doi: 10.1016/j.ejca.2019.08.032 - [link]
Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-?-blokkers - Nederlands Tijdschrift voor Geneeskunde
Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - European Journal of Surgical Oncology, 45 (5), 825-831 - doi: 10.1016/j.ejso.2019.01.225 - [link]
Hedwig Blommestein, CHY van Beurden-Tan, Margreet Franken, Carin Groot, Pieter Sonneveld & S Zweegman (2019) - Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis - Haematologica, 104 (5), 1026-1035 - doi: 10.3324/haematol.2018.206912
Hans Westgeest, Malou Kuppen, AJM Van den Eertwegh, Ronald Wit, J Coenen, HP van den Berg, N Mehra, IM van Oort, L Fossion, MP Hendriks, HJ Bloemendal, ACM van de Luijtgaarden, DT Huinink, ACM van den Bergh, JG Bosch, MB Polee, N Weijl, AM Bergman, Carin Groot & WR Gerritsen (2019) - Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands - Clinical Genitourinary Cancer, 17 (5), E946-E956 - doi: 10.1016/j.clgc.2019.05.018
Samare Huls, Chiara Lauren Whichello, Job Exel, Carin Groot & Esther Grob (2019) - What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review - Value in Health, 22 (11), 1318-1328 - doi: 10.1016/j.jval.2019.04.1930
Nathalie Uyl, Evert Jonge, Carin Groot, Caroline Marel & JJ Duvekot (2019) - Difficult epidural placement in obese and non-obese pregnant women: a systematic review and meta-analysis - International Journal of Obstetric Anesthesia, 40, 52-61 - doi: 10.1016/j.ijoa.2019.05.011
Marscha Holleman, Carin Groot, S Goodall & Naomi Linden (2019) - Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data - Value in Health, 22, 322-331 - doi: 10.1016/j.jval.2018.08.007
Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
Malou C.P. Kuppen, Hans M. Westgeest, Alphonsus J.M. van den Eertwegh, Reindert J.A. van Moorselaar, Inge M. van Oort, Juleon L.L.M. Coenen, A. C.M.Fons van den Bergh, Niven Mehra, Diederik M. Somford, Andre M. Bergman, Daan Ten Bokkel Huinink, Laurent Fossion, Maud M. Geenen, Mathijs P. Hendriks, Addy C.M. van de Luijtgaarden, Marco B. Polee, Nir I. Weijl, Agnes J. van de Wouw, Ronald de Wit, Carin A. Uyl-de Groot & Winald R. Gerritsen (2019) - Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer - European urology oncology, 4 (4), 618-627 - doi: 10.1016/j.euo.2019.09.005 - [link]
Olena Mandrik, OI (Obinna) Ekwunife, F (Filip) Meheus, Hans Severens, SK (Stefan) Lhachimi, Carin Groot & R Murillo (2019) - Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening. - Cancer Medicine, 8 (18), 7846-7858 - doi: 10.1002/cam4.2498 - [link]
Frederick Thielen, Hedwig Blommestein, LEM Oosten, FG Calkoen, AC Lankester, JJ Zwaginga, K Le Blanc, A Redondo, F Sánchez?Guijo, M Algeri, F (Franco) Locatelli, WE Fibbe & Carin Groot (2018) - Second?line treatment for acute graft?versus?host disease with mesenchymal stromal cells: A decision model. - European Journal of Haematology, 101 (5), 676-683 - doi: 10.1111/ejh.13158 - [link]
A Jochems, Brenda Leeneman, Margreet Franken, MG Schouwenburg, MJB Aarts, Alexander Akkooi, F van den Berkmortel, AJM Van den Eertwegh, G Groenewegen, JWB de Groot, JBAG Haanen, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, AJ ten Tije, G Vreugdenhil, MWJM Wouters, Carin Groot & JJM van der Hoeven (2018) - Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands - Anti-Cancer Drugs, 29 (6), 572-578 - doi: 10.1097/CAD.0000000000000629
Margreet Franken, Brenda Leeneman, A Jochems, MG Schouwenburg, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JWB de Groot, JJM van der Hoeven, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, G Vreugdenhil, MWJM Wouters, M Zeijl, JBAG Haanen & Carin Groot (2018) - Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands - Anti-Cancer Drugs, 29 (6), 579-588 - doi: 10.1097/CAD.0000000000000628
Carin Groot & Bob Löwenberg (2018) - Sustainability and affordability of cancer drugs: a novel pricing model - Nature Reviews Clinical Oncology, 15 (7), 405-406 - doi: 10.1038/s41571-018-0027-x
Margreet Franken, Tim Kanters, JL Coenen, P De Jong, HR Koene, Elly Lugtenburg, Agnes Jager & Carin Groot (2018) - Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands - Anti-Cancer Drugs, 29 (8), 791-801 - doi: 10.1097/CAD.0000000000000648
Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
Amir Ansaripour, Carin Groot & Ken Redekop (2018) - Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"' - Pharmacoeconomics (Print), 36 (3), 381-382 - doi: 10.1007/s40273-018-0620-y
Carin Groot & B Lowenberg (2018) - Reply to 'Economic comments on proposal for a novel cancer drug pricing model' - Nature Reviews Clinical Oncology, 15 (9), 588 - doi: 10.1038/s41571-018-0084-1
Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
Carin Groot & Bob Löwenberg (2018) - Reply to 'Response to proposal for a novel cancer drug pricing model' - Nature Reviews Clinical Oncology, 15 (8), 528-529 - doi: 10.1038/s41571-018-0063-6
Carin Groot, Ellen Rooijen, CJA Punt & CP Pescott (2018) - Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands - Health Economics Review, 8 (1), 13 - doi: 10.1186/s13561-018-0197-3
Amir Ansaripour, K Zendehdel, N Tadayon, F Sadeghi, Carin Groot & Ken Redekop (2018) - Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran - PLoS One (online), 13 (10) - doi: 10.1371/journal.pone.0205079
Chrissy Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma - Journal of Clinical Oncology, 35 (12), 1312-+ - doi: 10.1200/jco.2016.71.1663
Avinash Dinmohamed, PC Huijgens, M Brink, EFM Posthuma, Carin Groot, NMA Blijlevens, Jan Cornelissen & O Visser (2017) - Het hemato-oncologieregister van de Nederlanse Kankerregistratie: verleden, heden en toekomst - Nederlands Tijdschrift voor Hematologie, 14 (2), 55-63
Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
A Jochems, MG Schouwenburg, Brenda Leeneman, Margreet Franken, AJM Van den Eertwegh, J Haanen, H Gelderblom, Carin Groot, MJB Aarts, F van den Berkmortel, WAM Blokx, MC Cardous-Ubbink, G Groenewegen, JWB de Groot, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, AJ ten Tije, G Vreugdenhil, MWJM Wouters & JJM van der Hoeven (2017) - Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands - European Journal of Cancer, 72, 156-165 - doi: 10.1016/j.ejca.2016.11.021
N van der Linden, ML Bongers, VMH Coupe, EF Smit, HJM Groen, A Welling, F Schramel & Carin Groot (2017) - Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands - Clinical Lung Cancer, 18 (5), E341-E347 - doi: 10.1016/j.cllc.2015.11.011
Hedwig Blommestein, Carin Groot & S Zweegman (2017) - De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg - Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281
LEM Oosten, MED Chamuleau, Frederick Thielen, LC de Wreede, Claire Siemes, Jeanette Doorduijn, OS Smeekes, MJ Kersten, L Hardi, JW Baars, AMP Demandt, WBC Stevens, GW Nijland, Carin Groot, PM Kluin, D de Jong & H Veelken (2017) - Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens - Annals of Hematology, 97 (2), 255-266 - doi: 10.1007/s00277-017-3167-7 - [link]
ML Bongers, D De Ruysscher, C Oberije, P Lambin, Carin Groot, J Belderbos & VMH Coupe (2017) - MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER - International Journal of Technology Assessment in Health Care, 33 (6), 681-690 - doi: 10.1017/s0266462317000939
CHY van Beurden-Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Reply to X. Armoiry et al - Journal of Clinical Oncology, 35 (25), 2976 - doi: 10.1200/JCO.2017.73.7569
Frederick Thielen, Hedwig Blommestein & Carin Groot (2016) - Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease - Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110 - doi: 10.1016/j.bbmt.2016.08.022
Amir Ansaripour, Carin Groot, M Foroozanfar, S Rahimimoghadam & Ken Redekop (2016) - Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran - Journal of Cancer Policy, 9, 8-13 - doi: 10.1016/j.jcpo.2016.05.005
Leander Buisman, Maureen Molken, D Postmus, JJ Luime, Carin Groot & Ken Redekop (2016) - The early bird catches the worm: early cost-effectiveness analysis of new medical tests - International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53 - doi: 10.1017/S0266462316000064
Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
Saskia Groot, Stefan Sleijfer, Ken Redekop, E Oosterwijk, JB Haanen, LALM Kiemeney & Carin Groot (2016) - Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry - BMC Cancer, 16, 364 - doi: 10.1186/s12885-016-2395-x
Saskia Groot, Ken Redekop, Stefan Sleijfer, E Oosterwijk, A Bex, LALM Kiemeney & Carin Groot (2016) - Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry - Urology, 95, 121-127 - doi: 10.1016/j.urology.2016.04.042
Annemieke Leunis, Ken Redekop & Carin Groot (2016) - Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. - Value in Health, 19 (6), 834-843 - doi: 10.1016/j.jval.2016.05.008
Raoel Maan, Remziye Zaim, Adriaan Meer, JJ Feld, H Wedemeyer, JF Dufour, F Lammert, MP Manns, S Zeuzem, Bettina Hansen, HLA Janssen, Bart Veldt, Rob Knegt & Carin Groot (2016) - Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis - Journal of Gastroenterology and Hepatology, 31 (11), 1851-1859 - doi: 10.1111/jgh.13373
M D Franken, Ellen Rooijen, Carin Groot, MGH van Oijen & M Koopman (2016) - Cost-effectiveness in colorectal cancer: challenges on quality and comparability - Colorectal Cancer, 5 (1), 21-31 - doi: 10.2217/crc.15.33
Hans Westgeest, Carin Groot, RJA van Moorselaar, Ronald Wit, ACM van den Bergh, JLLM Coenen, HP Beerlage, MP Hendriks, MMEM Bos, P van den Berg, AJ van de Wouw, T Spermon, MO Boerma, MM Geenen, LW Tick, MB Polee, HJ Bloemendal, I Cordia, FPJ Peters, AI de Vos, J van den van den Bosch, AJM Van den Eertwegh & WR Gerritsen (2016) - Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry - European Urology, 4 (5), 694-701 - doi: 10.1016/j.euf.2016.09.008
Hedwig Blommestein, PC Huijgens & Carin Groot (2016) - De toegevoegde waarde van gegevens uit de dagelijkse praktijk. - Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208
DC Malone, N S Berg, K Claxton, LP Jr. Garrison, M Ijzerman, K Marsh, P J Neumann, M Sculpher, A Towse, Carin Groot & MC Weinstein (2016) - International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework - Journal of Clinical Oncology, 34 (24), 2936-+ - doi: 10.1200/jco.2015.64.4328
Carin Groot, Werner Brouwer, JM de Maeseneer & Jaap Verweij (2015) - Primary care in cancer control: towards mature cancer care - Lancet Oncology, 16 (22), 1226-1227 - doi: 10.1016/S1470-2045(15)00294-6 - [link]
L Mohseninejad, Chantal Gils, Carin Groot, E Buskens & TL (Talitha) Feenstra (2015) - Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer - Value in Health, 18, 84-90 - doi: 10.1016/j.jval.2014.10.008
Naomi Linden, J Buter, CP Pescott, RI Lalisang, JP de Boer, A de Graeff, CML van Herpen, RJ Baatenburg de Jong & Carin Groot (2015) - Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands - European Archives of Oto-Rhino-Laryngology, 273 (2), 455-464 - doi: 10.1007/s00405-015-3495-y
Hedwig Blommestein, Margreet Franken & Carin Groot (2015) - A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry - Pharmacoeconomics (Print) - doi: 10.1007/s40273-015-0260-4
KM (Kim Marleine) Holtzer - Goor, MR Schaafsma, P Joosten, EF Posthuma, S Wittebol, PC Huijgens, EJ Mattijssen, G Vreugdenhil, WG Peters, Z Erjavec, PW Wijermans, SM Daenen, KG van der Hem, MH van Oers & Carin Groot (2015) - Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study - Quality of Life Research, 24 (12), 2895-2906 - doi: 10.1007/s11136-015-1039-y
ML Bongers, D De Ruysscher, C Oberije, P Lambin, Carin Groot & VMH Coupe (2015) - Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity - Medical Decision Making, 36 (1), 86-100 - doi: 10.1177/0272989X15574500
ML Bongers, VMH (Veerle) Coupe, D De Ruysscher, C Oberije, P Lambin & Carin Groot (2015) - Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy: A Model-Based Evaluation - International Journal of Radiation Oncology Biology Physics, 91 (4), 857-865 - doi: 10.1016/j.ijrobp.2014.12.012 - [link]
Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
JG (Jennifer G.) Gaultney, Margreet Franken, Carin Groot, Ken Redekop, PC Huijgens, Ronnie Holt, HM Lokhorst & Pieter Sonneveld (2015) - Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement - Health Policy, 119 (2), 186-194 - doi: 10.1016/j.healthpol.2014.11.010
Naomi Linden, EF Smit & Carin Groot (2015) - Real-world costs of laboratory tests for non-small cell lung cancer - Clinical Chemistry and Laboratory Medicine, 53 (8), e187-e189 - doi: 10.1515/cclm-2014-1262
Naomi Linden, GB Flach, R de Bree & Carin Groot (2015) - Cost–utility of sentinel lymph node biopsy in cT1–T2N0 oral cancer - Oral Oncology, 53, 20-26 - doi: 10.1016/j.oraloncology.2015.11.011 - [link]
Naomi Linden, ML Bongers, VMH Coupe, EF Smit, HJM Groen, A Welling, FMNH Schramel & Carin Groot (2015) - Costs of non-small cell lung cancer in the Netherlands - Lung Cancer, 91, 79-88 - doi: 10.1016/j.lungcan.2015.10.015
Babette Prick, JJ Duvekot, PE Moer, N van Gemund, PCM van der Salm, Gerard Jansen, Dick Rhenen, BW Mol & Carin Groot (2014) - Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage - Vox Sanguinis, 107 (4), 381-388 - doi: 10.1111/vox.12181
Hedwig Blommestein, DE Issa, M Pompen, G Ten Hoor, M Hogendoorn, P Joosten, S Zweegman, PC Huijgens & Carin Groot (2014) - Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study - European Journal of Haematology, 92, 398-406 - doi: 10.1111/ejh.12264
P Fennema, TJ Heyse & Carin Groot (2014) - Cost-effectiveness and clinical implications of advanced bearings in total knee arthroplasty: a long-term modeling analysis. - International Journal of Technology Assessment in Health Care, 30 (2), 218-225 - doi: 10.1017/S0266462314000129
Chantal Gils, Saskia Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154
Naomi Linden, Chantal Gils, CP Pescott, J Buter, MR Vergeer & Carin Groot (2014) - Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck - European Archives of Oto-Rhino-Laryngology, 272 (8), 2007-2016 - doi: 10.1007/s00405-014-3106-3
Carin Groot, EGE de Vries, Jaap Verweij & R O' Sullivan (2014) - Dispelling the myths around cancer care delivery: It's not all about costs - Journal of Cancer Policy, 2, 22-29 - doi: 10.1016/j.jcpo.2014.01.001
Hedwig Blommestein, Margreet Franken, Silvia Verelst, M (Michel) van Agthoven, PC Huijgens & Carin Groot (2014) - Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? - Netherlands Journal of Medicine, 72 (4), 235-241 - [link]
Amir Ansaripour, Carin Groot, Adri Steenhoek & Ken Redekop (2014) - The Drug Reimbursement Decision-Making System in Iran - Value in Health Regional Issues, 3, 174-181 - doi: 10.1016/j.vhri.2014.04.010
Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
Annemieke Leunis, Ken Redekop, Carin Groot & Bob Löwenberg (2014) - Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study - European Journal of Haematology, 93 (3), 196-206 - doi: 10.1111/ejh.12324
Babette Prick, Gerard Jansen, EAP Steegers, WCJ Hop, Marie-louise Bot, Carin Groot, BMC Akkerboom, MMA van Alphen, KWM Bloemenkamp, KE Boers, HA Bremer, A Kwee, AJ Loon, GCH Metz, DNM Papatsonis, JAM van der Post, MM Porath, RJP Rijnders, FJME Roumen, HCJ Scheepers, DH Schippers, NWE Schuitemaker, RH Stigter, MD Woiski, BWJ (Ben) Mol, Dick Rhenen & JJ Duvekot (2014) - Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial - Bjog-An International Journal of Obstetrics and Gynaecology, 121 (8), 1005-1014 - doi: 10.1111/1471-0528.12531
Chantal Gils, Saskia Groot, Ken Redekop, M Koopman, CJA Punt & Carin Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6
JG (Jennifer G.) Gaultney, Margreet Franken, Siok Swan Tan, Ken Redekop, PC Huijgens, Pieter Sonneveld & Carin Groot (2013) - Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents - Journal of Clinical Pharmacy and Therapeutics, 38, 41-47 - doi: 10.1111/jcpt.12020
Annemieke Leunis, Ken Redekop, Kees Montfort, Bob Löwenberg & Carin Groot (2013) - The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia - Pharmacoeconomics (Print) - doi: 10.1007/s40273-013-0058-1
Wing Tong, Inge Sluis, CJM (Cathelijne) Alleman, RRL van Litsenburg, GJL Kaspers, Rob Pieters & Carin Groot (2013) - Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy - Haematologica, 98 (5), 753-759 - doi: 10.3324/haematol.2012.073510
Margreet Franken, Chantal Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010
KM (Kim Marleine) Holtzer - Goor, CAM Bouwmans - Frijters, MR Schaafsma, O de Weerdt, P Joosten, EFM Posthuma, S Wittebol, PC Huijgens, EJM Mattijssen, G Vreugdenhil, H Visser, WG Peters, Z Erjavec, PW Wijermans, SMGJ Daenen, KG van der Hem, MHJ van Oers & Carin Groot (2013) - Real-world costs of chronic lymphocytic leukaemia in the Netherlands - Leukemia Research, 38, 84-90 - doi: 10.1016/j.leukres.2013.10.029
Naomi Linden, Chantal Gils, CP Pescott, J Buter & Carin Groot (2013) - Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results - European Archives of Oto-Rhino-Laryngology, 271 (6), 1673-1678 - doi: 10.1007/s00405-013-2646-2
Freek Lötters, B Lucius, HP Sleeboom, A Bochove, RCM Pelger, FL Erdkamp & Carin Groot (2013) - Voorkomen van botcomplicaties bij patienten met borstkanker: een doelmatigheidsmodel - Nederlands Tijdschrift voor Oncologie, 10 (3), 109-116
R Crott, Matthijs Versteegh & Carin Groot (2013) - An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences - Quality of Life Research, 22 (5), 1045-1054 - doi: 10.1007/s11136-012-0220-9.
JG (Jennifer G.) Gaultney & Carin Groot (2013) - Efficient allocation of novel agents in multiple myeloma: a work in progress - Oncologist, 18 (1), 5-7 - doi: 10.1634/theoncologist.2012-0484.
Matthijs Versteegh, Annemieke Leunis, Carin Groot & Elly Stolk (2012) - Condition- Specific Preference-Based Measures: Benefit or Burden? - Value in Health, 15, 504-513 - doi: 10.1016/j.jval.2011.12.003
JG (Jennifer G.) Gaultney, Ken Redekop, Pieter Sonneveld & Carin Groot (2012) - Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value - Expert Review of Anticancer Therapy, 12 (6), 839-854 - doi: 10.1586/era.12.42 - [link]
Matthijs Versteegh, Annemieke Leunis, JJ Luime, M Boggild, Carin Groot & Elly Stolk (2012) - Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D - Medical Decision Making, 32, 554-568 - doi: 10.1177/0272989X11427761
Hedwig Blommestein, Silvia Verelst, PC Huijgens, NMA Blijlevens, Jan Cornelissen & Carin Groot (2012) - Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study - Annals of Hematology, 91 (12), 1945-1952 - doi: 10.1007/s00277-012-1530-2
Annemieke Leunis, Hedwig Blommestein, PC Huijgens, NMA Blijlevens, Mojca Lavrencic & Carin Groot (2012) - The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands - Leukemia Research, 37, 245-250 - doi: 10.1016/j.leukres.2012.09.018
Chantal Gils, M Koopman, L (Linda) Mol, Ken Redekop, Carin Groot & CJA Punt (2012) - Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands - Acta Oncologica, 51, 57-64 - doi: 10.3109/0284186X.2011.633930
E Bastiaannet, Carin Groot, AH Brouwers, EJ van der Jagt, OS Hoekstra, WJ Oyen, F Verzijlbergen, B van Ooijen, JF Thompson & HJ Hoekstra (2012) - Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III Melanoma - Annals of Surgery, 255 (4), 771-776 - doi: 10.1097/SLA.0b013e31824a5742
RRL van Litsenburg, Carin Groot, Hein Raat, GJL Kaspers & RJBJ Gemke (2011) - Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia With Chemotherapy Only: The Influence of New Medication and Diagnostic Technology - Pediatric Blood & Cancer, 57 (6), 1005-1010 - doi: 10.1002/pbc.23197
SA Baeten, RMPM (Rob) Baltussen, Carin Groot, JFP Bridges & LW (Louis Wilhelmus) Niessen (2011) - Reducing Disparities in Breast Cancer Survival - The Effect of Large-Scale Screening of the Uninsured - Breast Journal, 17 (5), 548-549 - doi: 10.1111/j.1524-4741.2011.01135.x
JG (Jennifer G.) Gaultney, E Sanhueza, JJ Janssen, Ken Redekop & Carin Groot (2011) - Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia - Pharmacogenomics, 12 (3), 411-421 - doi: 10.2217/pgs.10.187
JG (Jennifer G.) Gaultney, Ken Redekop, Pieter Sonneveld & Carin Groot (2011) - Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology - European Journal of Cancer, 47 (10), 1458-1467 - doi: 10.1016/j.ejca.2011.04.005
Silvia Verelst, Fabian Termorshuizen, Carin Groot, MR Schaafsma, Rianne Ammerlaan, S Wittebol, HAM Sinnige, S Zweegman, M van Marwijk-Kooy, R van der Griend, HM Lokhorst, Pieter Sonneveld & PW Wijermans (2011) - Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. - Annals of Hematology, 90 (12), 1427-1439 - doi: 10.1007/s00277-011-1224-1
Naomi Linden, Carin Groot & PW Wijermans (2010) - ‘Patient’s en doctor’s delay’ bij multipelmyeloom en de ziekte van Waldenström - Nederlands Tijdschrift voor Hematologie, 7 (6), 218-223
SA Baeten, RMPM (Rob) Baltussen, Carin Groot, J Bridges & LW (Louis Wilhelmus) Niessen (2010) - Incorporating Equity-Effeciency Interactions in Cost-Effectiveness Analysis-Three Approaches Applied to Breast Cancer Control - Value in Health, 13 (5), 573-579 - doi: 10.1111/j.1524-4733.2010.00718.x
Siok Swan Tan, Chantal Gils, Margreet Franken, Leona Roijen & Carin Groot (2010) - The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology - Value in Health, 13 (6), 712-719 - doi: 10.1111/j.1524-4733.2010.00740.x
Carin Groot, Saskia Groot & Adri Steenhoek (2010) - The economics of improved cancer survival rates: better outcomes, higher costs - Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292 - doi: 10.1586/erp.10.27
Carin Groot, A Senft, R de Bree, R Leemans & OS Hoekstra (2010) - Chest CT and Whole-Body 18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients - Journal of Nuclear Medicine, 51 (2), 176-182 - doi: 10.2967/jnumed.109.067371
Carin Groot, R Stupp & Martin Bent (2009) - Cost-effectiveness of temozolomide for the threatment of newly diagnosed glioblastoma multiforme - Expert review of pharmacoeconomics & outcomes research, 9 (3), 235-241 - doi: 10.1586/erp.09.15
FFH Rutten, Carin Groot & Arnold Vulto (2009) - Innovative payment systems for medicines in Europe - EJHP Practice, 15 (3), 60-62
ACG van Hooren, Werner Brouwer, R de Bree, OS Hoekstra, CR Leemans & Carin Groot (2009) - The cost-effectiveness of FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy - European Archives of Oto-Rhino-Laryngology, 266 (9), 1441-1448
CAM Bouwmans - Frijters, J Janssen, P Huijgens & Carin Groot (2009) - Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia - Journal of Medical Economics, 12 (2), 164-169 - doi: 10.3111/13696990903149479
JM Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & Carin Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - Cancer, 112 (6), 1337-1344
W Nijdam, Peter Levendag, I Noever-Smit, Paul Schmitz & Carin Groot (2008) - Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery - Brachytherapy, 7, 343-350 - doi: 10.1016/j.brachy.2008.05.001
R de Bree, L van der Putten, OS Hoekstra, DJ Kuik, Carin Groot, H van Tinteren, CR Leemans & M Boers (2007) - A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurent laryngeal carcinoma after radiotherapy - Contemporary Clinical Trials, 28, 705-712 - doi: 10.1016/j.cct.2007.03.009
Siok Swan Tan, Carin Groot, PC Huijgens & WE Fibbe (2007) - Stem cell transplantation in Europe: trends and prospects - European Journal of Cancer, 43, 2359-2365 - doi: 10.1016/j.ejca.2007.08.020
Marieke Krol, MI Koopman & Carin Groot (2007) - A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer - Expert Opinion on Pharmacotherapy, 8, 1313-1328 - doi: 10.1517/14656566.8.9.1313
LM (Leida) Lamers, Carin Groot & Ivonne Buijt (2007) - The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis - Pharmacoeconomics (Print), 25 (7), 591-603 - doi: 10.2165/00019053-200725070-00005
R de Bree, R Reith, JJ Quak, Carin Groot, M (Michel) van Agthoven & CR Leemans (2007) - Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysis - Clinical Otolaryngology, 32, 275-282 - doi: 10.1111/j.1365-2273.2007.01466.x
Wideke Nijdam, Peter Levendag, D Fuller, R Schulz, JGHG Prevost, I Noever-Smit & Carin Groot (2007) - Robotic radiosurgery vs. brachytherapy as a boost to intensity modulated radiotherapy for tonsillar fossa and soft palate tumors: the clinical and economic impact of an emerging technology - Technology Cancer Research Treatment, 6, 611-619
MT (Martijn) Groot, RMPM (Rob) Baltussen, Carin Groot, BO Anderson & GN Hortobagyi (2006) - Costs and Health Effects of Breast Cancer Interventions in Epidemiologically Different Regions of Africa, North America and Asia - Breast Journal, 12 (1), 81-90 - doi: 10.1111/j.1075-122X.2006.00206.x
MT (Martijn) Groot, PC Huijgens & Carin Groot (2006) - Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe - European Journal of Hospital Pharmacy Practice, 12, 30-36
M (Michel) van Agthoven, HAG Heule-Dieleman, PPM Knegt, JHAM Kaanders, RJ Baatenburg de Jong, B (Bernd) Kremer, CR Leemans, HAM Marres, JJ Manni, JA Langendijk, Peter Levendag, RE Tjho-Heslinga, JMA de Jong, Maarten Boer & Carin Groot (2006) - Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas - European Archives of Oto-Rhino-Laryngology, 263, 729-737 - doi: 10.1007/s00405-006-0062-6
GJM Herder, H Kramer, OS Hoekstra, EF Smit, J Pruim, H van Tinteren, EFI Comans, P (Paul) Verboom, Carin Groot, A Welling, MA Paul, MM Boers, PE Postmus, GJ Teule & HJM Groen (2006) - Traditional Versus up-Front (18F) Fluorodeoxyglucose Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study - Journal of Clinical Oncology, 24 (12), 1800-1806
Carin Groot (2006) - Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care - European Journal of Cancer, 42, 2862-2866 - doi: 10.1016/j.ejca.2006.08.008
MGH Niezen, Elly Stolk, Adri Steenhoek & Carin Groot (2006) - Inequalities in oncology care: Economic consequences of high cost drugs - European Journal of Cancer, 42, 2887-2892 - doi: 10.1016/j.ejca.2006.07.009
Carin Groot, JB Vermorken, MG Hanna, P (Paul) Verboom, MT (Martijn) Groot, Gouke Bonsel, CJLM Meijer & HM Pinedo (2005) - Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits - Vaccine, 23 (17-18), 2379-2387 - doi: 10.1016/j.vaccine.2005.01.015
MT (Martijn) Groot, Elly Lugtenburg, J Hornberger, PC Huijgens & Carin Groot (2005) - Cost-effectiveness of rituximab (MabThera (R)) in diffuse large B-cell lymphoma in the Netherlands - European Journal of Haematology, 74 (3), 194-202 - doi: 10.1111/j.1600-0609.2004.00368.x
M (Michel) van Agthoven, HAG Heule-Dieleman, Maarten Boer, JHAM Kaanders, RJ Baatenburg de Jong, B (Bernd) Kremer, CR Leemans, HAM Marres, JJ Manni, JA Langendijk, Peter Levendag, RE Tjho-Heslinga, JMA de Jong, Carin Groot & PPM Knegt (2005) - Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas - Radiotherapy and Oncology, 74 (3), 337-344 - doi: 10.1016/j.radonc.2005.01.003
M (Michel) van Agthoven, Pieter Sonneveld, LF Verdonck & Carin Groot (2005) - Cost determinants in aggressive non-Hodgkin's lymphoma - Haematologica, 90 (5), 661-671
Carin Groot, J Mcdonnell, HJM Groen, D Radice & G Velde (2005) - Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small lung cancer: Results of a Markov chain model - European Journal of Hospital Pharmacy Science, 2, 37-41
Carin Groot, Ivonne Buijt, IJM Gloudemans, GJ Ossenkoppele, HP van den Berg & PC Huijgens (2005) - Health related quality of life in patients with multiple myeloma undergoing a double transplantation - European Journal of Haematology, 74 (2), 136-143 - doi: 10.1111/j.1600-0609.2004.00346.x
M (Michel) van Agthoven, MHH Kramer, Pieter Sonneveld, KG van der Hem, PC Huijgens, PW Wijermans, HC Kluin-Nelemans, MR Schaafsma, DH Biesma, V Mattijssen, Carin Groot & A (Anton) Hagenbeek (2005) - Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma - Haematologica, 90 (10), 1422-1432
Carin Groot & G Giaccone (2005) - Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? - Current Opinion in Oncology, 17 (4), 392-396 - doi: 10.1097/01.cco.0000168535.25330.6a
MT (Martijn) Groot, Elly Lugtenburg, J Hornberger, PC Huijgens & Carin Groot (2005) - (MabThera) in diffuse large B-cell lymphoma in the Netherlands - European Journal of Haematology, 74, 194-202
J Doorduyn, Ivonne Buijt, Ronnie Holt, M (Michel) van Agthoven, Pieter Sonneveld & Carin Groot (2004) - Economic evaluation of prophylacticgranulocyte colony-stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma - Haematologica, 89 (9), 1109-1117
M (Michel) van Agthoven, C Segeren, Ivonne Buijt, Carin Groot, Ronnie Holt, HM Lokhorst & Pieter Sonneveld (2004) - A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose - European Journal of Cancer, 40, 1159-1169
Wideke Nijdam, Peter Levendag, I Noever-Smit, Carin Groot & M (Michel) van Agthoven (2004) - Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate - International Journal of Radiation Oncology Biology Physics, 59 (2), 488-494 - doi: 10.1016/j.ijrobp.2003.11.002
M (Michel) van Agthoven, Carin Groot, Pieter Sonneveld & A (Anton) Hagenbeek (2004) - Economic assessment in the management of non-Hodgkin's lymphoma - Expert Opinion Pharmacotherapy, 12, 2529-2548
M (Michel) van Agthoven, S Wittebol, LM (Leo) Budel, Carin Groot & MHH Kramer (2004) - Overleving van patienten met aggressief non-hodgkinlymfoom - Nederlands Tijdschrift voor Geneeskunde, 148, 88-93
M (Michel) van Agthoven, S Wittebol, LM (Leo) Budel, Carin Groot & MHH Kramer (2004) - Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line teratment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice - Nederlands Tijdschrift voor Geneeskunde, 148, 88-93
MT (Martijn) Groot, M (Michel) van Agthoven, Bob Löwenberg, R Willemze & Carin Groot (2004) - The role of cost analysis in the evaluation of the development of medical technology.The case of allogenic stem-cell transplantation - Nederlands Tijdschrift voor Geneeskunde, 148, 480-484
MT (Martijn) Groot, PC Huijgens, Carin Groot & P Wijermans (2004) - Costs of multiple myeloma and associated skeletal-related events in the Netherlands - Expert review of pharmacoeconomics & outcomes research, 4, 565-572 - doi: 10.1586/14737167.4.5.565
Carin Groot, J den Hartog & JGM Derksen (2004) - Cost-effectiveness and quality of life of granulocyte-colony stimulating factor after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial - Gynec Repr Biol, 114, 77-82
J Doorduyn, Ronnie Holt, GW van Imhoff, KG van der Hem, MHH Kramer, MHJ van Oers, GJ Ossenkoppele, MR Schaafsma, LF Verdonck, GEG Verhoef, MMC Steijaert, Ivonne Buijt, Carin Groot, M (Michel) van Agthoven, AH (Andries) Mulder & Pieter Sonneveld (2003) - CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma - Journal of Clinical Oncology, 21 (16), 3041-3050
M (Michel) van Agthoven, Pieter Sonneveld, A (Anton) Hagenbeek & Carin Groot (2003) - A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma - Hematology Journal, 4, 399-409 - doi: 10.1038/sj.thj.6200323
MT (Martijn) Groot, GJ Ossenkoppele, MHH Kramer, G Boom, PC Huijgens & Carin Groot (2003) - Medicamenteuze behandeling van chronische myeloïde leukemie: een kosteneffectiviteitsanalyse van 1e en 2e lijnsbehandeling - Nederlands Tijdschrift voor Geneeskunde, 50, 1460-1465
MT (Martijn) Groot, CGG Boeken Kruger, RCM Pelger & Carin Groot (2003) - Costs of prostate cancer, metastatic to the bone, in The Netherlands - European Urology, 43, 226-232 - doi: 10.1016/S0302-2838(03)00007-1
P (Paul) Verboom, H van Tinteren, OS Hoekstra, EF Smit, JHAM van den Bergh, AJM Schreurs, RALM Stallaert, PCM van Velthoven, EFI Comans, FW Diepenhorst & Carin Groot (2003) - Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study - European Journal of Nuclear Medicine and Molecular Imaging, 30, 1444-1449
Peter Levendag, Wideke Nijdam, M (Michel) van Agthoven & Carin Groot (2002) - Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high techology - is it worth the cost? - Brachytherapy, 1, 11-20 - doi: 10.1016/S1538-4721(02)00005-3
M (Michel) van Agthoven, LM (L.) Faber, Carin Groot, Pieter Sonneveld, LF Verdonck, R Willemze, JC Kluin-Nelemans, Bob Löwenberg & PC Huijgens (2002) - Cost analysis of first-line CHOP (-like) chemotherapy regimens for patients with intermediate or high-grade non-Hodgkin's lymphoma - European Journal of Haematology, 69, 213-220 - doi: 10.1034/j.1600-0609.2002.02772.x
M (Michel) van Agthoven, Carin Groot, WJ Fokkens, Joop Merwe & Jan Busschbach (2002) - Cost analysis of regular and filgrastim treatment in patients with refractory chronic rhinosinusitis - Rhinology, 40, 69-74
M (Michel) van Agthoven, Carin Groot, LF Verdonck, Bob Löwenberg, AVMB Schattenberg, M Oudshoorn, A (Anton) Hagenbeek, Jan Cornelissen & R Willemze (2002) - Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia - Bone Marrow Transplantation, 30, 243-251 - doi: 10.1038/sj.bmt.1703641
E Vellenga, M (Michel) van Agthoven, AJ Croockewit, LF Verdonck, P Wijermans, MHJ van Oers, Charles Volkers, GW van Imhoff, T Kingma, Carin Groot & WE Fibbe (2001) - Autologous peripheral blood stem cell transplantation in patients with relaps lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study - British Journal of Haematology, 114 (2), 319-326 - doi: 10.1046/j.1365-2141.2001.02926.x
Carin Groot, J den Hartog, PC Huijgens, R Willemze & Martin Ineveld (2001) - Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands - Journal of Hematotherapy & Stem Cell Research, 10, 187-192 - doi: 10.1089/152581601750098499
N (Nan) Li, M (Michel) van Agthoven, PHB Willemse & Carin Groot (2001) - A cost-utility analysis of several second-line chemoharapy schemes in patients with metastatic breast cancer - Anti-Cancer Drugs, 12 (6), 533-540
M (Michel) van Agthoven, E Vellenga, WE Fibbe, T Kingma & Carin Groot (2001) - Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma Hodgkin's disease: a prospective - European Journal of Cancer, 37 (14), 1781-1789 - doi: 10.1016/S0959-8049(01)00198-8
M (Michel) van Agthoven, Martin Ineveld, Maarten Boer, CR Leemans, PPM Knegt, GB Snow & Carin Groot (2001) - The costs of head and neck oncology, primary tumour recurrent tumours and long-term follow-up - European Journal of Cancer, 37 (17), 2204-2211 - doi: 10.1016/S0959-8049(01)00292-1
M (Michel) van Agthoven, WJ Fokkens, Joop Merwe, EM van Bolhuis, Carin Groot & Jan Busschbach (2001) - Quality of life effects of filgrastim treatment in patients with refractory chronic rhinosinusitis - American Journal of Rhinology, 15 (4), 231-238
Carin Groot (2000) - Cost-effectiveness of stem-cell transplantations in non-Hodgkin's lymphoma in the Netherlands - ONE, 1 (8), 49-52
Carin Groot, S Wait & Ivonne Buijt (2000) - Economics and health-related quality of life in antiemetic therapy: recommendations for trial design - European Journal of Cancer, 36, 1522-1535 - doi: 10.1016/S0959-8049(00)00132-5
LM (L.) Faber, M (Michel) van Agthoven, Carin Groot, Bob Löwenberg & PC Huijgens (2000) - Diagnostiek en behandeling van het non-Hodgkin-lymfoom in Nederland: variëteit in richtlijnen en in de praktijk - Nederlands Tijdschrift voor Geneeskunde, 144 (25), 1223-1227
Carin Groot, GJ Ossenkoppele, Ivonne Buijt & PC Huijgens (1999) - Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995 - Journal of Hematotherapy & Stem Cell Research, (8), 619-625 - doi: 10.1089/152581699319786
Carin Groot, GJ Ossenkoppele, Ivonne Buijt & PC Huijgens (1999) - Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transpantation in Non-Hodgkin's Lymphoma - Pharmacoeconomics (Print), 15 (3), 305-311 - doi: 10.2165/00019053-199915030-00009
Carin Groot, Bob Löwenberg, E Vellenga, S Suciu, R Willemze & FFH Rutten (1998) - Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia - British Journal of Haematology, 100, 629-636
Carin Groot, Bob Löwenberg, E Vellenga, S Suciu, R Willemze & FFH Rutten (1998) - Cost-effectiveness and quality- of- life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia - British Journal of Haematology, 100, 629-636
J Bonnema, A van Wersch, AN Geel, J Pruyn, PIM@ Schmitz, Carin Groot & T (Theo) Wiggers (1998) - Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer - European Journal of Cancer, 34 (13), 2015-2020
Carin Groot & CR Touw (1998) - Economic evaluation of cancer treatments: methodological and practical issues - Anti-Cancer Drugs, 9, 833-841
Ivonne Buijt, Carin Groot & PC Huijgens (1998) - Costs of intensive treatment and follow-up of patients with multiple myeloma - Anti-Cancer Drugs, 9, 889-897
Carin Groot (1997) - Farmaco-economische evaluaties gekoppeld aan klinische studies - Ziekenhuisfarmacie, (2), 109-112
Carin Groot, E Vellenga, EGE de Vries, Bob Löwenberg, GJ Stoter & FFH Rutten (1997) - Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia: results of a randomised placebo-controlled trial - Pharmacoeconomics (Print), 12 (3), 351-360
Carin Groot, E Vellenga, EGE de Vries, Bob Löwenberg, Gerrit Stoter & FFH Rutten (1997) - Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy-Related Febrile Neutropenia - Pharmacoeconomics (Print), (12), 351-360
E Vellenga, Carin Groot, Gerrit Stoter, Bob Löwenberg & EGE de Vries (1996) - Sneller herstel van leukocyten door hematopoëtische groeifactor bij patiënten met door chemotherapie veroorzaakte granulocytopenie en koorts, maar geen kortere opnameduur - Nederlands Tijdschrift voor Geneeskunde, 140 (32), 1650-1655
C Williams, D Coyle, J Hutton, A Gray, T Jefferson, G Karlsson, K Kesteloot, Carin Groot & S Wait (1996) - European School of Oncology Advisory Report to the Commission of the European Communities for the "Europe Against Cancer Programme" Cost-effectiveness in Cancer Care - European Journal of Cancer, 31a (9), 1410-1424
LS Hofstra, Carin Groot & E Vellenga (1996) - Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters - Medical Oncology and Tumor Pharmacotherapy, (13), 177-184
E Vellenga, Carin Groot, Ronald Wit, HJ Keizer, Bob Löwenberg, MA ten Haaft, ThJM de Witte, CAH Verhagen, GJ Stoter, FFH Rutten, NH Mulder, WM Smid & EGE de Vries (1996) - Randomized Placebo-Controlled Trial of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Chemotherapy-Related Febrile Neutropenia - Journal of Clinical Oncology, 14 (2), 619-627
Carin Groot, E Vellenga & FFH Rutten (1996) - An Economic Model to Assess the Savings From a Clinical Application of Haematopoietic Growth Factors - European Journal of Cancer, 32a (1), 57-62
Carin Groot, PC Huijgens & FFH Rutten (1996) - Colony-Stimulating Factors and Peripheral Blood Progenitor Cell Transplantation - Pharmacoeconomics (Print), 10 (1), 23-35
Carin Groot, SY Okhuijsen, A (Anton) Hagenbeek, PC Huijgens, GW van Imhoff, Bob Löwenberg, LF Verdonck & FFH Rutten (1995) - Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands - Bone Marrow Transplantation, (15), 605-610
Carin Groot, A (Anton) Hagenbeek, LF Verdonck, FFH Rutten & Bob Löwenberg (1995) - Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL) - Bone Marrow Transplantation, (16), 463-470

Brenda Leeneman, Hedwig M. Blommestein, Veerle M.H. Coupé, Mathijs P. Hendriks, Wim H.J. Kruit, Peter W. Plaisier, Serge Van Ruth, Albert J. Ten Tije, Michel W.J.M. Wouters, Margreet G. Franken & Carin A. Uyl-De Groot (2021) - Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands - Melanoma Research, 31 (3), 249-257 - doi: 10.1097/cmr.0000000000000732

Matthijs Versteegh, Arthur Attema & Carin Groot (2019) - Is verlies winst? Stoppen met TNF-alfaremmers - Nederlands Tijdschrift voor Geneeskunde, 163 - [link]
R de Kleijn, C Hagen, Carin Groot, P Pasker de Jong & P Ter Wee (2015) - PREDICTION OF CARE BURDEN OF PATIENTS UNDERGOING HAEMODIALYSIS: DEVELOPMENT OF A MEASURING TOOL - Journal of Renal Care, 1-7 - doi: 10.1111/jorc.12109
Maureen Molken & Carin Groot (2012) - Naar gepast gebruik van geneesmiddelen - Economisch-Statistische Berichten, 97 (4644S), 87-93
PC Huijgens, EFM Posthuma, Jan Willem Coebergh, LV van de Poll-Franse, Carin Groot & Pieter Sonneveld (2010) - Een 'population based registry' voor hemato-oncologie - Nederlands Tijdschrift voor Hematologie, 7 (8), 321-324
Carin Groot & Adri Steenhoek (2007) - Nieuwe 'dure' kankergeneesmiddelen en kosteneffectiviteitsanalyses: hoe is de stand van zaken? - IKR-bulletin (Rotterdam), 31, 28-30
RR de Bree, OS Hoekstra, L van der Putten, M Boers, Carin Groot & CR Leemans (2005) - Recidief larynxcarcinoom na radiotherapie-PET studie: RELAPS - Nederlands Tijdschrift voor Oncologie, 2, 119
MT (Martijn) Groot, N van Overbeke, L Annemans & Carin Groot (2002) - Kostenanalyse van het medisch handelen bij gemetastaseerd colorectaal carcinoom: een vergelijking tussen 5-FU Leucovorine (LV) en UFT Leuvovorin (LV) - Pharmaceutisch Weekblad, 137 (20), 714-721
E (Einte) Elsinga & Carin Groot (1996) - Dure geneesmiddelen in het ziekenhuis: De Taxol zaak nader belicht - ZorgVisie (Maarssen), 26 (5), 8-11
FFH Rutten & Carin Groot (1996) - Pharmacoeconomic Evaluation in Clinical Practice - Clinical Pharmacist, 1 (1), 30-35
FFH Rutten & Carin Groot (1995) - Economic evaluation and cancer treatment: Limits to growth - Helix. Amgen's Magazine of Biotechnology, 4 (3), 41-47

Maureen Molken, Carin Groot & FFH Rutten (2010) - Een handleiding voor economische evaluatiestudies in de gezondheidszorg Tweede herziene druk - Elsevier

Carin Groot (2000) - Uitgangspunten en opzet van onderzoek - Elsevier gezondheidszorg

Evalyn E.A.P. Mulder, Dirk J. Grünhagen, Stefan Sleijfer, Carin A. Uyl-de Groot & Astrid A.M. van der Veldt (2021) - Adjuvant treatment in patients with melanoma: The planning of scanning - European Journal of Cancer, 157, 306-307 - doi: 10.1016/j.ejca.2021.08.041

Carin Groot (1995) - Economic evaluation of cancer treatments - BMG

Carin Groot (2011) - 'Dure' diagnostiek en kangergeneesmiddelen: de andere kant van de ongelijkheid II - Instituut Beleid & Management Gezondheidszorg

Carin Groot & DT (Danja) Stierman (2014) - Resultaten monitor overheveling TNF-alfaremmers, groeihormonen, oncologische- en andere geneesmiddelen - Institute for Medical Technology Assessment / Instituut voor Beleid en Management Gezondheidszorg Erasmus Universiteit Rotterdam
Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA

KM (Kim Marleine) Holtzer - Goor, CAM Bouwmans - Frijters, MR Schaafsma & Carin Groot (2011) - A cost of illness and equality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands - Instituut Beleid & Management Gezondheidszorg
M (Michel) van Agthoven, LM (L.) Faber & Carin Groot (2001) - Diagnostiek, behandeling en follow-up van het intermediair en hooggradig Non-Hodgkin Lymfoom. Kosten van protocollaire en niet-protocollaire behandelingen
M (Michel) van Agthoven, MT (Martijn) Groot & Carin Groot (2001) - Kosten van allogene stamceltransplantaties

Kimberley Hubens, Marieke Krol, Joanna Coast, Michael F. Drummond, Werner B.F. Brouwer, Carin A. Uyl-de Groot & Leona Hakkaart-van Roijen (2021) - Measurement Instruments of Productivity Loss of Paid and Unpaid Work - Value in Health, 24 (11), 1686-1699 - doi: 10.1016/j.jval.2021.05.002
Martijn Simons, Michiel Van De Ven, Veerle M.H. Coupé, Manuela Joore, Maarten IJzerman, Erik Koffijberg, GWJ Frederix, Carin Uyl-De Groot, Edwin Cuppen, Wim Van Harten & Valesca Retèl (2021) - Early technology assessment of using whole genome sequencing in personalized oncology - Expert Review of Pharmacoeconomics and Outcomes Research, 21 (3), 343-351 - doi: 10.1080/14737167.2021.1917386
Marloes E. Clarijs, Jacob Thurell, Friedrich Kühn, Carin A. Uyl-De Groot, Elham Hedayati, Maria M. Karsten, Agnes Jager & Linetta B. Koppert (2021) - Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients - Cancers, 13 (10) - doi: 10.3390/cancers13102308

David G.J. Cucchi, Tobias B. Polak, Gert J. Ossenkoppele, C.A. (Carin) Uyl-de Groot, Jacqueline Cloos, Sonja Zweegman & Jeroen J.W.M. Janssen (2021) - Two decades of targeted therapies in acute myeloid leukemia - Leukemia, 35 (3), 651-660 - doi: 10.1038/s41375-021-01164-x

Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran

Master Thesis HE

Year: 2021
Year Level: master, master
Course Code: GW4592M

Master Thesis HEPL

Level: master
Year: 2021
Year Level: master
Course Code: GW4555M

Afstudeerproject

Level: bachelor 3
Year: 2021
Year Level: bachelor 3
Course Code: GW311

prof.dr. (Carin) CA Uyl - de Groot

More information

Profile

Master Thesis HE

Master Thesis HEPL

Afstudeerproject

Compare @count study programme

@title

prof.dr. (Carin) CA Uyl - de Groot

More information

Profile

Publications (228)

Article (214)

Academic (203)

Popular (1)

Professional (10)

Book (1)

Chapter (1)

Comment/Letter to the editor (1)

Doctoral Thesis (1)

Inaugural speech (1)

Report (5)

Academic (2)

Professional (3)

Review article (4)

Academic (3)

Popular (1)

Awards (1)

Teaching (3)

Master Thesis HE

Master Thesis HEPL

Afstudeerproject